Min Ho Park1, Ji Shin Lee, Jung Han Yoon. 1. Department of Surgery, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju, Republic of Korea.
Abstract
BACKGROUND: CX3CL1 is the only CX3C chemokine that can chemoattract T cells, natural killer (NK) cells, and dendritic cells (DCs). The role of CX3CL1 in breast carcinoma remains unknown. METHODS: Immunohistochemical staining for CX3CL1, CD8, CD57, and CD1a was performed on 204 breast carcinoma specimens using tissue microarray blocks to determine whether CX3CL1 expression correlated with a good prognosis and antitumor immunity. RESULTS: The number of stromal CD8+ T cells, intratumoral CD1a+ DCs, and stromal CD57+ NK cells were significantly increased in the high CX3CL1 expression group compared with those in the low CX3CL1expression group. Patients with high CX3CL1 expression had a significantly better disease-free and overall survival than those with low CX3CL1 expression (P=0.002 and P<0.001, respectively). CX3CL1 expression was identified as one of the independent prognostic factors for disease-free and overall survival (P=0.046 and P=0.010, respectively). CONCLUSION: The expression of CX3CL1 by tumor cells appears to enhance the recruitment of CD8+ T cells, CD57+ NK cells, and CD1a+ DCs, thereby bringing about a better prognosis in breast carcinoma. CX3CL1 is a new prognostic biomarker and may be a novel candidate for development of a more effective therapeutic strategy for breast carcinoma.
BACKGROUND:CX3CL1 is the only CX3C chemokine that can chemoattract T cells, natural killer (NK) cells, and dendritic cells (DCs). The role of CX3CL1 in breast carcinoma remains unknown. METHODS: Immunohistochemical staining for CX3CL1, CD8, CD57, and CD1a was performed on 204 breast carcinoma specimens using tissue microarray blocks to determine whether CX3CL1 expression correlated with a good prognosis and antitumor immunity. RESULTS: The number of stromal CD8+ T cells, intratumoral CD1a+ DCs, and stromal CD57+ NK cells were significantly increased in the high CX3CL1 expression group compared with those in the low CX3CL1expression group. Patients with high CX3CL1 expression had a significantly better disease-free and overall survival than those with low CX3CL1 expression (P=0.002 and P<0.001, respectively). CX3CL1 expression was identified as one of the independent prognostic factors for disease-free and overall survival (P=0.046 and P=0.010, respectively). CONCLUSION: The expression of CX3CL1 by tumor cells appears to enhance the recruitment of CD8+ T cells, CD57+ NK cells, and CD1a+ DCs, thereby bringing about a better prognosis in breast carcinoma. CX3CL1 is a new prognostic biomarker and may be a novel candidate for development of a more effective therapeutic strategy for breast carcinoma.
Authors: Sigrid Dubois; Kevin C Conlon; Jürgen R Müller; Jennifer Hsu-Albert; Nancy Beltran; Bonita R Bryant; Thomas A Waldmann Journal: Cancer Immunol Res Date: 2017-08-25 Impact factor: 11.151
Authors: Yiyi Yan; Siyu Cao; Xin Liu; Susan M Harrington; Wendy E Bindeman; Alex A Adjei; Jin Sung Jang; Jin Jen; Ying Li; Pritha Chanana; Aaron S Mansfield; Sean S Park; Svetomir N Markovic; Roxana S Dronca; Haidong Dong Journal: JCI Insight Date: 2018-04-19
Authors: Jie Huang; Wei Hu; Limin Hu; Rebecca A Previs; Heather J Dalton; Xiao-Yun Yang; Yunjie Sun; Michael McGuire; Rajesha Rupaimoole; Archana S Nagaraja; Yu Kang; Tao Liu; Alpa M Nick; Nicholas B Jennings; Robert L Coleman; Robert B Jaffe; Anil K Sood Journal: Mol Cancer Ther Date: 2016-03-23 Impact factor: 6.261
Authors: Richard N Hanna; Caglar Cekic; Duygu Sag; Robert Tacke; Graham D Thomas; Heba Nowyhed; Erica Herrley; Nicole Rasquinha; Sara McArdle; Runpei Wu; Esther Peluso; Daniel Metzger; Hiroshi Ichinose; Iftach Shaked; Grzegorz Chodaczek; Subhra K Biswas; Catherine C Hedrick Journal: Science Date: 2015-10-22 Impact factor: 47.728